IDEC-C2B8 chimeric anti-CD20 antibody (MAB): Safety and clinical activity in the treatment of patients (PTS) with relapsed low-grade or follicular (IWF:A-D) non-Hodgkin's lymphoma (NHL)

被引：0
|
作者：
GrilloLopez, AJ [1 ]
Varns, C [1 ]
Waldichuk, C [1 ]
Dallaire, BK [1 ]
Rosenberg, J [1 ]
McClure, A [1 ]
Shen, D [1 ]
机构：
[1] IDEC PHARMACEUT CORP,SAN DIEGO,CA
来源：
BRITISH JOURNAL OF HAEMATOLOGY | 1996年 / 93卷
关键词：
D O I：
暂无
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
引用
收藏
页码：1072 / 1072
页数：1
相关论文
共 50 条
  • [31] IDEC-C2B8: Results of a phase I multiple-dose trial in patients with relapsed non-Hodgkin's lymphoma
    Maloney, DG
    GrilloLopez, AJ
    Bodkin, DJ
    White, CA
    Liles, TM
    Royston, I
    Varns, C
    Rosenberg, J
    Levy, R
    JOURNAL OF CLINICAL ONCOLOGY, 1997, 15 (10) : 3266 - 3274
  • [32] Rituximab:: Pharmacokinetic/pharmacodynamic correlations of extended dosing in patients (pts) with relapsed low-grade or follicular non-Hodgkin's lymphoma (LG/F NHL).
    Saven, A
    Grillo-López, AJ
    Janakiraman, N
    Alkuzweny, B
    Beck, TM
    Piro, L
    Rosenberg, J
    McClure, A
    White, CA
    BLOOD, 2000, 96 (11) : 730A - 730A
  • [33] Treatment of a relapsed radio- and chemotherapy refractory primary CNS lymphoma with the anti-CD-20 antibody IDEC-C2B8
    Schulz, H
    Pels, H
    Rehwald, U
    Rosenberg, J
    Schlegel, U
    Diehl, V
    Engert, A
    NEUROLOGY, 2001, 56 (08) : A411 - A411
  • [34] IDEC-Y2B8 (90)yttrium anti-CD20 radioimmunotherapy of relapsed non-Hodgkin's lymphoma (NHL): Interim results of a Phase I/II trial.
    Witzig, T
    Wiseman, C
    White, CA
    Solinger, A
    Gordon, L
    Raubitschek, A
    Emmanoulides, C
    Royston, I
    Parker, E
    Chinn, P
    GrilloLopez, A
    BLOOD, 1997, 90 (10) : 2606 - 2606
  • [35] Y-90 anti-CD20 monoclonal antibody (IDEC-Y2B8) dosimetry calculated from In-111 anti-CD20 in patients with low and intermediate grade B-cell non-Hodgkin's lymphoma.
    Wiseman, GA
    Witzig, TE
    Dunn, WL
    Chin, P
    Salinger, AM
    JOURNAL OF NUCLEAR MEDICINE, 1997, 38 (05) : 1062 - 1062
  • [36] Targeted anti-cancer therapy using a chimeric anti-CD20 antibody in the treatment of non-Hodgkin's B cell lymphoma
    Anderson, DR
    Varns, C
    IMMUNOLOGY, 1996, 89 : SI112 - SI112
  • [37] Phase I study of IDEC-Y2B8: 90-yttrium labeled anti-CD20 monoclonal antibody therapy of relapsed non-Hodgkin's lymphoma
    GrilloLopez, AJ
    Chinn, P
    Morena, R
    Varns, C
    Parker, E
    Solinger, AM
    BLOOD, 1995, 86 (10) : 207 - 207
  • [38] Treatment of patients with low-grade B-cell lymphoma with the combination of chimeric anti-CD20 monoclonal antibody and CHOP chemotherapy
    Czuczman, MS
    Grillo-López, AJ
    White, CA
    Saleh, M
    Gordon, L
    LoBuglio, AF
    Jonas, C
    Klippenstein, D
    Dallaire, B
    Varns, C
    JOURNAL OF CLINICAL ONCOLOGY, 1999, 17 (01) : 268 - 276
  • [39] IDEC-Y2B8 (Y-90 conjugated anti-CD20) dosimetry calculated from In-111 anti-CD20 in patients with low and intermediate grade B-cell non-Hodgkin's lymphoma (NHL) emphasis on bone marrow (BM).
    Wiseman, GA
    Solinger, AM
    GrilloLopez, A
    Stabin, M
    Dunn, WL
    Witzig, TE
    Spies, S
    Gordon, L
    Raubitschek, A
    Margolin, K
    Karvelis, K
    Janakiraman, N
    Silverman, DH
    Emmanoulides, C
    Royston, I
    Chinn, P
    Parker, E
    Carter, W
    White, CA
    BLOOD, 1997, 90 (10) : 2273 - 2273
  • [40] Chimeric anti-CD20 monoclonal antibody (Mabthera) in remission induction and maintenance treatment of relapsed follicular non-Hodgkin's lymphoma: a phase III randomized clinical trial - Intergroup Collaborative Study
    van Oers, MHJ
    Hagenbeek, A
    Van Glabbeke, M
    Teodorovic, I
    ANNALS OF HEMATOLOGY, 2002, 81 (10) : 553 - 557
12345